Pharmacoeconomics Basics
On this page
Direct answer
If a new antihypertensive costs ten times more but prevents twice the strokes, someone must decide whether that exchange is worth it — and pharmacoeconomics is the discipline that makes the exchange measurable. It identifies, measures and compares the costs and outcomes of drug therapy: direct costs (medicines, hospital beds, laboratory tests), indirect costs (lost wages and productivity) and intangible costs (pain and suffering), weighed against outcomes through four standard analyses — cost-minimisation (CMA), cost-effectiveness (CEA), cost-utility (CUA, cost per QALY) and cost-benefit (CBA, both sides in rupees). The incremental cost-effectiveness ratio, ICER, is the single number most papers ask you to compute.
What you must remember
- Direct medical costs: drug acquisition, dispensing, admissions, consultations, investigations; direct non-medical: travel, food, caregiver expenses; indirect: productivity lost to morbidity and mortality; intangible: suffering, rarely monetised.
- CMA (cost-minimisation analysis): used only when outcomes are proven equivalent — the analysis collapses to choosing the cheapest option.
- CEA (cost-effectiveness analysis): outcomes in natural units — cost per mmHg lowered, per infection cured, per life saved; suits single-outcome comparisons within one disease.
- CUA (cost-utility analysis): outcomes in QALYs — quality-adjusted life years, years of life weighted by quality of life on a 0-1 scale, elicited by instruments such as EQ-5D; allows comparisons across diseases.
- CBA (cost-benefit analysis): outcomes converted to money (willingness to pay), giving a benefit-cost ratio; powerful but ethically contested.
- ICER = (cost of new option − cost of comparator) / (effect of new option − effect of comparator); the price of each extra unit of benefit.
- Perspective matters: patient, hospital, payer or societal — the societal view counts indirect costs and changes conclusions.
- Discounting adjusts future costs and outcomes to present value (commonly around 3 per cent per year in health-economic practice); sensitivity analysis tests whether conclusions survive changed assumptions.
- Applications: formulary decisions by the PTC, pricing under DPCO and NPPA scrutiny, national programme choices, and guiding generic substitution policies such as Janaushadhi procurement.
An ICER computed and interpreted
Two regimens for a chronic disease: the standard therapy costs Rs 20,000 per patient-year and yields 8 quality-adjusted life years over the horizon; the new therapy costs Rs 80,000 and yields 10. ICER = (80,000 − 20,000)/(10 − 8) = 60,000/2 = Rs 30,000 per additional QALY. Now the decision layer: is Rs 30,000 per QALY acceptable? Countries and payers differ — there is no official Indian threshold, though bodies elsewhere have used benchmarks in the region of one to three times GDP per capita per QALY, a benchmark cited academically rather than adopted as policy. The method conclusion stands regardless: the new therapy is not "expensive" or "cheap" in isolation — it is a defined price for a defined gain, which is exactly what a formulary committee can deliberate on.
Then stress the number, because examiners reward the sensitivity step. If the new therapy's benefit drops to 9 QALYs, the ICER jumps to 60,000; if its price halves, it may dominate outright (cheaper and better). The same arithmetic governs programme decisions — the cost per TB patient cured under a regimen, or per episode of malaria prevented — which is how pharmacoeconomics earns its "fourth arm" place beside clinical evidence in formulary decisions.
The reasoning errors that fail answers
First, "cheapest is most cost-effective". Cost-effectiveness is a ratio; the cheapest option with poor outcomes can be dominated (more expensive per cure than an alternative), while a costly option can be highly effective per rupee. Second, CEA and CUA conflated: both compare cost to outcome, but CEA uses natural units within a disease while CUA uses QALYs and permits comparisons across diseases — the "which analysis would you use to compare an oncology drug with a cardiac drug?" answer is always CUA.
Third, ignoring perspective: an analysis from the hospital's view may ignore the wage losses the patient bears, and the societal perspective reverses the ranking — state the perspective before computing. Fourth, presenting an ICER without its comparator — an incremental ratio is meaningless unless both arms and the baseline are named. And fifth, forgetting that outcomes, not just costs, carry uncertainty: that is what sensitivity analysis exists to declare.
Frequently asked questions
Define pharmacoeconomics and classify costs with examples.
The study that identifies, measures and compares costs and outcomes of drug therapy; direct medical (drug, hospitalisation), direct non-medical (travel), indirect (lost productivity) and intangible (pain, suffering) costs.
Differentiate CEA, CUA, CBA and CMA.
CMA compares costs when outcomes are identical; CEA uses natural clinical units; CUA uses QALYs for cross-disease comparison; CBA monetises both costs and benefits to give a benefit-cost ratio.
What is a QALY and why is it useful?
A quality-adjusted life year — one year of perfect health, or the equivalent after weighting by quality of life (0 to 1); it merges survival and quality into one currency for comparing therapies across diseases.
Compute the ICER if drug A costs Rs 50,000 for 6 QALYs and drug B costs Rs 20,000 for 5 QALYs.
ICER = (50,000 − 20,000)/(6 − 5) = Rs 30,000 per additional QALY gained by choosing A over B.
Why is sensitivity analysis performed in pharmacoeconomic studies?
Because costs and outcomes are estimates with uncertainty; sensitivity analysis re-runs the calculation across plausible ranges to show whether the conclusion is robust or fragile.